期刊
CURRENT DIABETES REPORTS
卷 16, 期 12, 页码 -出版社
CURRENT MEDICINE GROUP
DOI: 10.1007/s11892-016-0816-5
关键词
Angiopoietins; Hypoxia; Neovascularization; Vascular leakage; Vascular endothelial growth factor; Vascular endothelial-protein tyrosine phosphatase
资金
- Aerpio Therapeutics
- Regeneron Therapeutics
- Genentech/Roche
- Alimera
- Allergan
- Applied Genetic Technologies
- AsclepiX
- Rxi
- Allegro
- Intrexon
- Regenxbio
- AbbVie
- Genzyme
- GlaxoSmithKline
- Oxford Biomedica
- Graybug
- Merck
Tie2 is a tyrosine kinase receptor located predominantly on vascular endothelial cells that plays a central role in vascular stability. Angiopoietin-1 (Angpt1), produced by perivascular cells, binds, clusters, and activates Tie2, leading to Tie2 autophosphorylation and downstream signaling. Activated Tie2 increases endothelial cell survival, adhesion, and cell junction integrity, thereby stabilizing the vasculature. Angiopoietin-2 (Angpt2) and vascular endothelial-protein tyrosine phosphatase (VE-PTP) are negative regulators increased by hypoxia; they inactivate Tie2, destabilizing the vasculature and increasing responsiveness to vascular endothelial growth factor (VEGF) and other inflammatory cytokines that stimulate vascular leakage and neovascularization. AKB-9778 is a small-molecule antagonist of VE-PTP which increases phosphorylation of Tie2 even in the presence of high Angpt2 levels. In preclinical studies, AKB-9778 reduced VEGF-induced leakage and ocular neovascularization (NV) and showed additive benefit when combined with VEGF suppression. In two clinical trials in diabetic macular edema (DME) patients, subcutaneous injections of AKB-9778 were safe and provided added benefit to VEGF suppression. Preliminary data suggest that AKB-9778 monotherapy improves diabetic retinopathy. These data suggest that Tie2 activation may be a valuable strategy to treat or prevent diabetic retinopathy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据